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ABSTRACT
Rationale Clinical trials are the gold standard for testing 
interventions. COVID-19 has further raised their public 
profile and emphasised the need to deliver better, faster, 
more efficient trials for patient benefit. Considerable 
overlap exists between data required for trials and data 
already collected routinely in electronic healthcare records 
(EHRs). Opportunities exist to use these in innovative 
ways to decrease duplication of effort and speed trial 
recruitment, conduct and follow- up.
Approach The National Institute of Health Research 
(NIHR), Health Data Research UK and Clinical Practice 
Research Datalink co- organised a national workshop to 
accelerate the agenda for ‘data- enabled clinical trials’. 
Showcasing successful examples and imagining future 
possibilities, the plenary talks, panel discussions, group 
discussions and case studies covered: design/feasibility; 
recruitment; conduct/follow- up; collecting benefits/harms; 
and analysis/interpretation.
Reflection Some notable studies have successfully 
accessed and used EHR to identify potential recruits, 
support randomised trials, deliver interventions and 
supplement/replace trial- specific follow- up. Some 
outcome measures are already reliably collected; others, 
like safety, need detailed work to meet regulatory 
reporting requirements. There is a clear need for system 
interoperability and a ‘route map’ to identify and access 
the necessary datasets. Researchers running regulatory- 
facing trials must carefully consider how data quality and 
integrity would be assessed. An experience- sharing forum 
could stimulate wider adoption of EHR- based methods in 
trial design and execution.
Discussion EHR offer opportunities to better plan clinical 
trials, assess patients and capture data more efficiently, 
reducing research waste and increasing focus on each 
trial’s specific challenges. The short- term emphasis should 
be on facilitating patient recruitment and for postmarketing 
authorisation trials where research- relevant outcome 
measures are readily collectable. Sharing of case studies 
is encouraged. The workshop directly informed NIHR’s 
funding call for ambitious data- enabled trials at scale. 
There is the opportunity for the UK to build upon existing 
data science capabilities to identify, recruit and monitor 
patients in trials at scale.
INTRODUCTION
Clinical trials will continue to be the gold 
standard for testing pharmacological, 
behavioural and policy interventions for 
the foreseeable future. The advent of the 
COVID-19 pandemic has raised the profile 
and importance of trials with the British 
public.1 For a large majority of conditions, 
late- phase randomised controlled trials are 
commonly long- term endeavours that are 
increasingly expensive, particularly indus-
try- led trials. There is considerable overlap 
between the data that triallists need to assess 
impact of interventions on patients and what 
is already routinely collected in patient’s 
health records. These routinely routinely 
collected data are reflected in local, regional 
or national datasets, collectively labelled here 
as ‘electronic health records’ (EHRs) (box 1). 
It is equally self- evident that safely making 
these routinely collected data available to 
researchers for purposeful access could 
decrease duplication of effort, reduce costs 
and may speed answers from some trials. The 
value of EHR in clinical trials is increasingly 
recognised by many organisations, including 
the UK (UK) Government as highlighted in 
the Life Sciences Industrial Strategy.2 3
The National Institute for Health Research 
(NIHR), Health Data Research UK (HDR 
UK) and the Clinical Practice Research 
Datalink (CPRD) (box 2) brought together 
UK researchers for a 1- day workshop in 
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October 2018 to discuss how clinical trials might undergo 
a step- change in the UK through being ‘data- enabled’. 
‘Data- enabled trials’ were defined for the workshop as 
introducing efficiencies in the following ways: improved 
study planning and feasibility assessments; more efficient 
recruitment, facilitated by accessing EHR to identify 
potential participants; efficient assessment of treatment 
benefits and potential harms by directly capturing routine 
EHR into the trial dataset; and more efficient study anal-
yses and interpretation, using standard EHR variables. 
Many lessons from the workshop are also relevant to clin-
ical trials more broadly.
Informed by this workshop, NIHR commissioned a 
cross- programme call for ‘Data- enabled trials’.4 Table 1 
contains a list of data- enabled trials that were funded as a 
result of this call.
While there is recognition that challenges exist to 
accessing and using all sources of EHR, great strides have 
already been made realising the potential for using avail-
able EHR in innovative ways to support the delivery of 
patient consented studies. The workshop’s spirit was there-
fore to focus on what had already been achievable and to 
consider imaginable solutions to current challenges and 
further possibilities that could be developed in the future 
at scale. Speakers and facilitators were asked ‘to demon-
strate existing capability and opportunities in the UK 
for undertaking data- enabled clinical trials, in particular 
showcasing the use of routine data to support different 
components of trial design and delivery, and regulatory 
considerations’. The workshop, which was attended by 
researchers from around the UK, included plenary talks, 
panel discussions, group discussions and the presenta-
tion of selected case studies. The elements were broadly 
grouped as: design and feasibility; recruitment; conduct 
and follow- up; collecting key data on benefits and harms; 
and analysis and interpretation. Here, we summarise and 
update some key issues that emerged in these areas in 
order to inform future discussions and research activities.
FINDINGS
Design and feasibility
Assessing the potential sufficiency of accrual is key to 
the planning and funding of all trials. Recruitment can 
be challenging both in prevalent and incident clinical 
conditions, particularly where potential participants 
are managing their chronic conditions in an environ-
ment away from active researchers. Robust and scalable 
processes to estimate the number of potential participants 
Box 1 What are routinely collected electronic health 
records?
There are vast amounts of data routinely being collected on patients, for 
example, in patient electronic health records (EHRs), as well as disease 
and patient registries. Such data are commonly called real- world data, 
reflecting that it is routinely collected while patients go about their reg-
ular lives, as opposed to being specifically collected in a clinical trial. 
Because the National Health Service (NHS) is a universal healthcare 
provider, free at point of care, the NHS EHR offers the possibility to col-
lect the longitudinal medical history of 98% of the UK population who 
uses the NHS. EHR therefore provides an excellent research tool for 
studying population health. Primary care EHRs are recorded by general 
practitioners (GPs) and contain longitudinal demographic and clinical 
patient information encompassing symptoms, diagnoses, prescribing, 
laboratory tests and data from hospital visits and admissions. Primary 
care EHR can be collected and made available for research in near real 
time. Secondary care records capture interactions that take place in a 
specific hospital and are event based, not longitudinal. Secondary care 
records are coded for reimbursement purposes and not usually by clini-
cians. There is a time lag between patient hospital visits and secondary 
care EHR data being made available for research and National Health 
Service planning purposes.
Box 2 National Institute for Health Research (NIHR), 
Health Data Research UK (HDR UK) and Clinical Practice 
Research Datalink (CPRD)
National Institute for Health Research
NIHR, a virtual organisation, is the research arm of the National Health 
Service. It comprises an academy of trainees and senior investigators, 
and systems to make research processing easier and faster, includ-
ing infrastructure, such as the clinical research network that plays a 
vital role in delivering research, and a number of research funding 
programmes. These include, for example, the NIHR Health Technology 
Assessment Programme, NIHR Health Services and Delivery Research 
and the NIHR Public Health Programme that fund prioritised health re-
search for the public on behalf of the Department of Health and Social 
Care.
Health Data Research UK
HDR UK is the national institute for health data science. The institute 
was established in 2018 as a joint strategic investment (HDR UK is 
funded by the Medical Research Council, the health research depart-
ments of England, Scotland, Wales and Northern Ireland (NIHR, Chief 
Scientist Office, Health and Care Research Wales, HSC Research and 
Development, respectively), the Economic and Social Research Council, 
the Engineering and Physical Sciences Research Council, the British 
Heart Foundation and Wellcome.) with an aim to ‘unite the UK’s health 
data to make discoveries that improve people’s lives’. Through ini-
tially six collaborative research sites across the UK and expanded to 
eight sites and seven specialist HDR Hubs, the Health Data Research 
Innovation Gateway and Health Data Research Alliance, the institute de-
velops advanced health data science tools and technologies to analyse 
large- scale and diverse health data to solve complex health challenges. 
One of the priority themes is ‘Better, faster, and more efficient clinical 
trials’.
Clinical Practice Research Datalink
CPRD is jointly sponsored by the Medicines and Healthcare products 
Regulatory Agency and NIHR and is part of the Department of Health 
and Social Care. CPRD is the UK Government’s dedicated real- world 
research service, which collects deidentified patient data on a daily 
basis from a network of one in every five GP practices across the UK, 
encompassing 25% of the UK population. The CPRD database includes 
longitudinal primary care records on a total 60 million patients collected 
over CPRD’s 30- year history, with a median patient follow- up time of 10 
years. Approximately 40% of CPRD’s GP practice network are research 
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that might be suitable for a particular study need to be 
established.
Historically, complex care pathways made it difficult 
to estimate and then locate potential trial participants, 
because they might enter the systems in a number of ways. 
Use of evidence from the EHR, where these are avail-
able, enables a more realistic estimate of the achievable 
sample size within specific geographical regions based 
on demographic and clinical information within EHRs. 
Key eligibility criteria such as demographic information, 
medication dose, laboratory results, timing of clinical 
events and comorbidities within the EHR allow rapid esti-
mates of the number of potentially eligible people that 
can be flagged as suitable for a trial.
In the UK, general practitioners (GPs) are the gate-
keepers to the National Health Service (NHS), and 
as such, primary care records hold information that 
includes demographic and clinical data derived from 
consultations within primary care as well as secondary 
care visits and from other sources such as laboratory 
tests. Primary care records, covering a patient’s medical 
history, are therefore a rich resource to carry out feasi-
bility assessments and to locate patients for studies that 
might take place in a range of settings. Timeliness of data 
is important. The primary care data that CPRD receives, 
encompassing 25% of UK population, is updated daily, 
and it forms the basis for feasibility assessments CPRD 
routinely carries out for academic and industry led 
trials.5 To further advance the use of EHR in supporting 
clinical trials, the NHS DigiTrials Health Data Research 
Hub for Clinical Trials was established by HDR UK in 
2019 to facilitate feasibility assessments in England, 
initially using secondary care Hospital Episode Statistics 
(HES).6 7
The usual method of locating patients for many studies 
involves manual searches of patient records at each GP 
practice. The COPE study,8 a patient- consented longi-
tudinal cohort study was one of the first studies in the 
UK exploring the use of EHR as a means of locating 
specific patients for enrolment into a study. The study, 
which sought to identify patients with chronic obstruc-
tive pulmonary disease (COPD) with prior exacerbation 
events (table 2) demonstrated that it is possible to use a 
primary care EHR database to screen, locate and recruit 
participants for research. This method ‘provides access 
to a cohort of patients while minimising input needed 
by GPs and allows researchers to examine healthcare 
usage and disease burden in more detail and in real- 
life settings’.8 CPRD carried out a centralised search 
for eligible patients in its database of pseudonymised 
patients, across a defined geographical region, and GPs 
in CPRD’s network were supplied with a list of potentially 
eligible patients based on the study inclusion and exclu-
sion criteria. The GP then carried out a clinical review 
and invited potentially suitable patients to attend specific 
centres in which recruitment and collection of bespoke 
data could be completed. This intermediate clinical vali-
dation step involving the GP confirming a patient’s eligi-
bility both facilitated locating high- quality patients and 
maintained patient confidentiality.
Table 2 Key points from COPE study
Study name (registration) Characterisation of COPD Exacerbations using Environmental Exposure Modelling (COPE)8
Sponsorship Academic – Imperial, MRC funded.
Clinical setting Chronic obstructive pulmonary in primary care, UK only: national.
Design Patient- consented longitudinal cohort study (non- randomised).
Size N=130.
Key outcome measure COPD exacerbations.
Rationale for presentation Design and feasibility.
Key discussion points The aim of the COPE study was to develop a method for predicting COPD exacerbations as 
a result of environmental exposures. Quality algorithmic query specification to identify patient 
cohorts in EHR relies on data quality. The algorithm for COPE was validated in a previous study 
by comparing the EHR records with additional information provided by GPs.60 The validated query 
was applied centrally to search for patients in the CPRD database. GPs were then contacted and 
asked to take part in confirming patient eligibility from a prescreened patient list.
Centralised searching of the EHR greatly minimised GP screening time in confirming patient 
eligibility. It was also possible for a GP to exclude patients who may not be suitable to take part 
(eg, due to caring for a sick relative). No algorithm could reliably account for these types of patient 
exclusions.
Lessons from the study were that it is feasible to recruit patients from EHR and readily collect 
data for long- term follow- up, although this method does depend on GP participation. Using EHR 
meant far less effort than manual screening of GP records. Because of the specificity of the EHR 
and clinical validation steps, more appropriate patients were approached, which reduced time 
needed for patient screening. Patients approached were keen to be involved in the study and as a 
result the enrolment was higher than using conventional methods.
COPD, chronic obstructive pulmonary disease; EHR, electronic health record; GPs, general practitioners.
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A large proportion of trials fail to recruit to time and 
target,9 and the funding wasted on these efforts may be 
better invested in modest pre- trial efforts to determine 
likely feasibility. Assessing potential numbers of patients 
can reasonably be done with near real time, longitudinal 
EHR (likely primary care datasets) or an administra-
tive EHR record, like HES, which is cross- sectional and 
broad but has a time delay. Given the demonstrated value 
of using an EHR evidence- based approach to assessing 
feasibility, research funding bodies will need to give 
careful consideration to how such work- up activities can 
be supported as dedicated funding for research usually 
starts only after the work to assess feasibility has been 
attempted. Key points to emerge for study planning using 
EHR were the importance of using a validated algorithm 
to search the data and the benefits of incorporating a 
clinical review to further refine the specificity of the 
search. These approaches can result in a much higher 
proportion of suitable and engaged patients presenting 
for detailed eligibility assessment at study sites.
Recruitment
Recruiting patients to research studies should be a stan-
dard part of routine practice. The majority of UK hospital 
trusts engage in research activity, and this is increasingly 
true in primary care with 40% of GP practices in England 
participating in research in 2018/2019.10 However, for 
most practitioners, there is limited time to spend with 
patients and often not enough time to explain research 
so lower burden approaches must be found.11 12 Searches 
of GP patient records for patients potentially suitable for 
clinical studies is not new. However, this is usually done 
by searching right through GP patient records on a local 
practice basis, which can be a burden for practice staff 
and introduce variability in interpretation of selection 
criteria. Centralised patient eligibility searches, such 
as those carried out by CPRD and North West eHealth, 
reduce the burden on practice staff by supplying the prac-
tice a list of potentially eligible patients located through 
standardised database searches against protocol inclusion 
and exclusion criteria.
Large- scale use of EHR for patient searches must 
take into account information governance regulations 
and the need to maintain patient confidentiality. One 
approach is to search pseudonymised patient data, where 
a patient’s identity is unknown to the researchers, as is 
the case with CPRD recruitment services. Potentially 
suitable patients are reidentified by their GP, thereby 
maintaining confidentiality between the patient and the 
clinician. In some cases, specific regulatory approvals 
may be granted by to individual researchers to obtain 
access to identifiable EHR patient data in order directly 
invite them into a clinical trial. Alternative methods for 
recruiting patients into prospective trials include estab-
lishing a cohort of patients or volunteers who are willing 
to take part in trials, such as the NHS Scotland SHARE 
scheme13 and COVID-19 vaccine trials portal14—volun-
teer datasets may contain phenotype or genotype data 
not available in clinical or administrative datasets— and 
pre- consenting trial participants to be reapproached 
about other studies, such as those following on from 
the INTERVAL trial (NCT01610635) of blood donation 
timing.15
EHRs are a tool that can be used to speed the pairing 
of willing patients with suitable trials.16 DECIDE is a trail-
blazing randomised pragmatic clinical effectiveness trial, 
involving a three- way partnership between academia, 
industry and CPRD, which recruited patients with type 2 
diabetes in a routine primary care setting, randomised to 
the licenced intervention or standard of care.17 The study 
involved centralised searches of CPRD’s primary care data 
to enable GPs in the CPRD network across all four UK 
nations to readily enrol suitable patients into the study 
when they presented for their routine diabetes checks. 
The novelty of this pragmatic clinical effectiveness study 
was that the study clinical data were captured directly from 
the patient’s primary care EHR and flowed into CPRD’s 
interventional research services platform (IRSP). The trial 
including randomisation was remotely managed via this 
central digital platform. The EHR derived study data were 
supplemented by electronic patient- reported outcomes 
collected by patients remotely logging into the IRSP. 
Table 3 summarises the key lessons from DECIDE, using 
real- time EHR to facilitate recruitment and trial manage-
ment. The DECIDE study demonstrates how it is possible 
to recruit patients across the UK into a randomised trial 
involving real- world type 2 diabetic patients, based on 
changing laboratory haemoglobin A1c (HbA1c) readings 
using dynamic data searches on primary care EHR data. 
This approach of using primary care data for time- bound 
patient recruitment offers great potential and generalis-
ability for phase II to phase IV patient recruitment, inde-
pendent of relying on busy clinicians identifying patients 
presenting at clinic visits.
The majority of clinical trial protocols involve inclu-
sion or exclusion variables that are time dependent, 
for example, timeframe from diagnoses, procedures 
or prescriptions. Furthermore, many trials will have a 
limited window of opportunity during which recruitment 
can take place for any individual potential participant. 
If patients are identified too late, the research invitation 
could arrive after it stopped being relevant; anecdotally, 
such irrelevant invitations have been confusing and upset-
ting to vulnerable populations. In these circumstances, 
the EHR source used to located suitable patients for trial 
recruitment must contain patient information that is 
both current and dynamic.
Primary care data can provide a longitudinal and timely 
resource for locating patients suitable for both incident 
and prevalence trials. For example, CPRD’s primary care 
records are updated daily and include hospital discharge 
information, so the system lends itself well to locating 
patients for trials taking place in primary or secondary 
care. GPs can also be alerted through system ‘pop- ups’ or 
dynamic daily refreshed patient lists, as for the DECIDE 
trial, which can support recruitment into incident trials 









pen: first published as 10.1136/bm




6 Sydes MR, et al. BMJ Open 2021;11:e043906. doi:10.1136/bmjopen-2020-043906
Open access 
for patients who present at the GP practice with acute or 
unmanaged conditions.
HES data can also be used to locate patients who 
have visited hospital and may be suitable for a trial. 
The ORION-4 trial is using a combination of HES data 
searches and patient questionnaires to recruit 15 000 
patients from across the UK with atherosclerotic cardio-
vascular disease.18 However, HES data has its limitation as 
it may only be available some months (often 3 months) 
after a patient hospital visit, it does not include a patient’s 
full medical history and may not include all poten-
tial patients, such where the condition was not severe 
enough to require a hospitalisation, for example, mild 
stroke. Some hospitals have developed their own EHR 
systems that support recruitment of patients presenting 
with acute conditions. However, there are currently no 
cross- hospital, interoperable electronic systems in use in 
secondary care that support dynamic recruitment.
Conduct and follow-up
Access to routine EHR for individuals participating in 
a trial to monitor their important and relevant health 
outcomes has been a fundamental challenge for many 
trials that have attempted access late in the trial. This 
has often involved a lengthy application process via 
a changing approval system, frequently resulting in a 
considerable lag between requesting and accessing data. 
Many researchers have persisted, recognising the huge 
potential for efficient use of EHR in the conduct and 
follow- up of trials, particularly large- scale national trials.
ASCEND19 20 was a UK- wide trial in 15 500 people with 
diabetes, evaluating the effect of aspirin and omega-3 fatty 
acids on the risk of cardiovascular events. The trial, whose 
key design features are summarised in table 4, used mail- 
based methods for recruitment, intervention delivery 
and follow- up, thereby avoiding the need for dedicated 
study sites. Initially, follow- up was by a paper- based ques-
tionnaire but, in the latter years of the trial, an online 
form was available for follow- up for those who preferred. 
Towards the end of the 7.5- year follow- up period, access 
to HES data was granted, which allowed missing outcome 
data to be recorded for participants who had not returned 
questionnaires. Preliminary unpublished comparisons in 
ASCEND between the questionnaire data and the EHR 
data showed good concordance, with analyses of the 
primary trial outcomes producing similar results irre-
spective of the data source used (L Bowman, personal 
communication, 2020).
Although the trial was beneficial for patients avoiding 
the need to travel to trial sites, it was labour intensive for 
the study team, involving mailing and phoning thousands 
Table 3 Key points from decide trial
Trial name (registration) DECIDE: Pragmatic Randomised 104 Week Multicentre Trial to Evaluate the Comparative 
Effectiveness of dapagliflozin and Standard of Care in Type-2 Diabetes17 (NCT02616666)
Sponsorship Industry then academic – AstraZeneca then Liverpool.
Clinical setting Type 2 diabetes mellitus on metformin and needing better glucose control in primary care 
setting, UK only: national.
Design Phase 4, randomised, open label, comparator trial.
Size N>800 (ongoing).
Key outcome measure Clinical success (glucose control) at 12 months.
Rationale for presentation Recruitment.
Key discussion points DECIDE is a clinical effectiveness trial comparing dapagliflozin, a sodium- glucose 
cotransporter-2 (SGLT2) inhibitor, to standard care (alternative medications such as sulfonylureas 
and DPP4 (Dipeptidyl- peptidase 4) inhibitors) in people with type 2 diabetes requiring second- 
line pharmacological treatment (after metformin). There was a limited window in which patients 
need to be approached before treatment is changed.
CPRD managed the trial using their interventional research services platform that supported 
general practitioners (GPs) and patients logging into the system. Algorithms were developed to 
carry out daily searches of primary care EHR for potentially eligible patients meeting prespecified 
criteria. The primary care team then reviewed the search list and enrol eligible patients into the 
study at their next routine scheduled visit.
Most of the data required for the trial was available in CPRD’s routinely collected dataset, 
thereby facilitating collection of primary and secondary outcome measures as well as 
identification and recruitment. Patient- reported outcome measures were collected electronically. 
Trial monitoring could therefore be carried out centrally.
Lessons from the trial are that EHR search algorithms are easy to set up, but feasibility 
assessments should take account of variability of coding and real- world clinical practice. 
Recruiting patients via EHR is achievable and allows easy collection of long- term data for follow- 
up, but as with all trials, it depends on GP and patient participation and engagement. Data 
enablement and platform technology allows real- time adaptation to real- time conditions.
CPRD, Clinical Practice Research Datalink; EHRs, electronic healthcare records.
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of participants and their GPs. Considerable efficiencies 
could have been possible if the HES data had been used as 
the main source of outcome information from the outset. 
Further benefits could be derived by accessing primary 
care data, as some cardiovascular events do not require 
hospitalisation and are consequently not captured in the 
HES data. The HES dataset is usually at least 3 months 
old. However, the ‘rawer’ form of HES, called Secondary 
Uses Service is being used in the RECOVERY trial to 
enable faster, although in extremis, assessment of health 
outcomes for patients with severe COVID-19 infection.
EHR can be used to assess the short- term and long- term 
impact of an intervention on health outcomes of indi-
vidual patients at participating sites. This can be through 
a patient- level intervention or via a randomised cluster 
trial where the intervention is applied at a site level. One 
such example is the REDUCE cluster randomised trial 
(ISRCTN95232781) embedded with the CPRD GP prac-
tice research network, which used a digital intervention 
versus standard of care to attempt to reduce unnecessary 
use of antibiotics for respiratory infections in primary 
care. In addition to using the EHR to monitor prescribing 
rates, EHR data were used to monitor patient health 
outcomes in the intervention and standard of care GP 
practice arms of the trial.11 Findings from ASCEND,19 20 
COPE8 and DECIDE11 support the advantages gained for 
data collection and follow- up by using EHR from the 
outset for patients recruitment.
The Office for National Statistics system has flagged 
people as participating in each of around 200 approved 
trials so that mortality data could be provided to the 
trial in due course. All EHR systems need to include 
this ability to flag for participation in a specific trial. 
Without flagging, triallists and EHR providers need 
to go through the linkage process. This increases costs 
against limited budgets, is disproportionately effortful 
and exposes a repeated risk of linkage errors. Both Public 
Health England (PHE) National Cancer Registration and 
Analysis Service (NCRAS) and NHS Digital are piloting 
approaches to trial flagging.
Collecting outcome data on benefits and harms
Access to timely data is key for any trial, and triallists must 
be able to report on safety and key outcome measures in 
a suitable timescale, including for the final analyses and 
for Data Monitoring Committee review of interim anal-
yses. Trials must meet the stringent regulatory timelines 
set out in UK law, which includes reporting to the compe-
tent authority, appropriate suspected unexpected serious 
adverse reactions (SUSAR), within short timelines that 
starts when the sponsor of the trial receives the informa-
tion from the clinical site.
The timely capture and reporting of certain safety 
outcome measures are critically important for the Clin-
ical Trials of Investigational Medicinal Products trials 
run under the clinical trials regulations, where a subset 
of serious adverse events (SAEs) must be reported to the 
regulator within a short, prescribed timescale of 7 or 15 
days. Researchers must quickly determine whether the 
SAE is a ‘reaction’ (Serious Adverse Reaction (SAR)) 
and, if so, whether this reaction is an ‘unexpected’ 
(SUSAR) according to clearly defined Reference Safety 
Table 4 Key points from Salford Lung Study
Trial name (registration) Salford lung Study21 (Extension=NCT03152669)
Sponsorship Industry – GlaxoSmithKline.
Clinical setting Chronic obstructive pulmonary, UK only: regional.
Design Early- phase, cluster randomised trial run in one geographic location.
Size N=7200.
Key outcome measure COPD exacerbation rates.
Rationale for presentation Conduct and follow- up, collecting data on benefits and harms.
Key discussion points The study was the first in the world to have evaluated the effectiveness and safety of a 
prelicenced medicine compared with standard of care when used in every day clinical practice 
in patients with COPD. Patients were randomised at their routine GP respiratory review visit 
and constant monitored through the 12- month study via real time data collection from GP and 
hospitals. Data was also collected from participating community pharmacies and from Office For 
National Statistics mortality and Secondary User Service national datasets and an out of hours 
phone service. A safety alerting and reporting system was established based on serious adverse 
events being initially flagged in the EHR followed by review by the safety team and the principal 
investigator prior to submission to the sponsor as appropriate.
Lessons learnt were to ensure at the design phase that all the safety and endpoints of the study 
could be readily captured and the importance of early engagement with the regulators and 
National Institute of Health and Care Excellence. The study demonstrated that safety monitoring 
in this type of real- wold study was effective, could be done close to real time and was highly 
configurable. Widespread adoption could improve safety and such systems lend themselves to 
novel trial designs.
COPD, chronic obstructive pulmonary disease; EHR, electronic healthcare record.
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Information. SAR and SUSAR are more likely in some 
treatment settings for example, cancer chemotherapy 
trials. ‘Seriousness’ definitions include, among others, 
‘hospitalisation’ or ‘prolongation of hospitalisation’, 
which may or may not be captured across different EHR 
systems.
Frequency of updates to routine EHR data depends on 
where in the system the data are collected. Primary care 
records, such as those received by CPRD, are updated 
daily, but administrative- focused EHR datasets, such as 
HES, may provide only a snapshot of data from some 
months ago. Trials using only periodically updated, 
routinely collected EHR generally cannot rely on these 
data for reporting purposes in regulatory timescales, in 
particular for safety monitoring. It is a key responsibility 
of researchers to understand the strengths and limita-
tions of any EHR data source, including its suitability to 
meet reporting requirements. A future involving inter-
connected real- time systems would allow investigators to 
reliably detect and report appropriate events.
The Salford Lung Studies were two industry- sponsored, 
late- phase randomised controlled trials (RCTs) that 
were the first studies in the world to have evaluated the 
effectiveness of a prelicenced medicine in a real- world 
setting. The study capitalised on access to primary care 
EHR, as well as community pharmacy data and electronic 
secondary care patient records embedded the regional 
hospitals. Altogether 7200 patients with COPD or asthma 
were monitoring in near real time for safety and outcomes 
using city- wide linked EHR.21 22 The study team met with 
the regulators to agree the outcome measure data and 
safety alerting and reporting systems, which were predi-
cated entirely on capture of routine data from near real- 
time primary and secondary care systems. As outlined 
in table 4, the studies successfully demonstrated that it 
is possible to run complex large- scale trials with configu-
rable near real- time safety monitoring systems that meet 
regulatory standards.
It is important to check up- front, in efficacy and effec-
tiveness trials that may be used for regulatory submission, 
whether routinely collected EHR would be accepted as 
source data by the relevant regulatory authorities. The 
Medicines and Healthcare products Regulatory Agency 
(MHRA) now considers using source data directly from 
each hospital’s EHR standard following digitalisation of 
health records. GCP inspections performed by the MHRA 
in the UK are performed against the requirements of the 
UK Clinical Trials Regulations, irrespective of whether 
the source data are electronic or paper in format. The 
MHRA recognises that there is no standardised method of 
recording clinical source data, especially in international 
multicentre trials (P Walker, personal communication, 
2020). Variations across sites include how many elec-
tronic systems make up the EHR, and how clinical data 
are reported through local laboratory electronic systems. 
It is therefore recommended each sponsor reviews the 
type of data required for their trial and how it would be 
recorded at site, including the various electronic systems 
that capture the source data and whether they are fit for 
purpose.
The source data and its underpinning EHR system 
needs to follow the ‘ALCOA+principles’ to be attribut-
able, legible, contemporaneous, original and accurate, 
as well as complete, consistent, enduring and available.23 
This ensures the data are reliable and that the elec-
tronic system is fit for its intended purpose. This should 
include appropriate access levels for investigator site trial 
teams, sponsor representatives and government regula-
tors and is supported by the International Conference 
on Harmonisation E6 R2 Addendum. Careful work is 
required to ensure that systems that collate data from 
multiple healthcare systems (eg, HES or registry data) 
follow these principles. Review of the data on regulatory 
inspection by the MHRA includes assessing whether the 
trial data can be reconstructed and that the previous 
requirements are met. Reconstruction includes assessing 
whether the system has an associated audit trail verifying 
who completed assessments and when and the ability to 
reconstruct any changes to the source data. Source data 
verification performed during MHRA inspections is 
always done on a risk- based approach, with a focus on the 
critical data for the trial and compliance with the clinical 
trials regulations, recognising that EHR systems are often 
designed with standard care not clinical trials in mind. 
The same risk- based approach should be taken by spon-
sors auditing their own trial data.
Analysis and interpretation
Many researchers desire collecting as much data as 
possible for their trial through routine EHR sources, 
thereby minimising the collection of data through 
trial- specific means. Reviewing metadata or deidenti-
fied samples of data, broadly representing the data that 
should be available for the sort of patients that could join 
a future trial, is recommended to determine which data-
sets include suitable variables to monitor health outcomes 
from EHR sources. In the case of cancer, PHE has devel-
oped Simulacrum to imitate some of the data held by 
NCRAS.24 The Health Data Research Innovation Gateway 
has been initiated by HDR UK as an open repository of 
data with associated metadata to accelerate discovery and 
access to existing health data research resources.25 Some 
argue that a common repository of data quality checks 
may be useful for researchers running data- enabled 
trials. Carrying out data utility assessments are a practical 
method of determining where EHR could substitute for 
trial- specific collection in future trials.26 27
Any single EHR dataset is not likely to collect all the 
necessary information, in a timely and consistent manner, 
that can be used to evaluate health outcomes across all trial 
arms. Table 5 sets out some of the lessons learnt during 
the Standard and New Antiepileptic Drugs II trial.28 29 
This trial for patients with epilepsy found that seizures, 
key to any epilepsy core outcome set, had not been well 
recorded in the accessible EHR sources. Initiatives such 
as the Core Outcome Measures in Effectiveness Trials 









pen: first published as 10.1136/bm




9Sydes MR, et al. BMJ Open 2021;11:e043906. doi:10.1136/bmjopen-2020-043906
Open access
are seeking to develop sets of core outcome measures 
(COSs) that are suitable to support RCTs, as well as audit, 
research and routine care. Researchers developing COS 
should strive to make them as similar as possible to both 
the information required in routine practice and the key 
outcomes needed by regulatory reviewers.
Routinely collected datasets have contrasting and comple-
mentary strengths: hospital EHR datasets are rich in specific 
areas but lack the wider medical history for each patients; 
GP EHR datasets capture the broader, longitudinal medical 
history but not all the specialist depth; and registry datasets 
may have rich healthcare data but for only a narrow patient 
subgroup; and central administrative datasets collating 
information across healthcare systems may be wide but not 
deep. Therefore, it may be necessary to use multiple data-
sets to analyse trial outcomes, and these datasets may need 
to be linked. Well- established processes exist to link data to 
trials, although delays can emerge from governance and 
data access issues.
Data linkage can be used to validate data collected on 
an individual trial participant from trial- specific source 
or other routine datasets. The comparisons of multiple 
sources can support assessment of generalisability and 
external validity for future research. The use of alterna-
tive data sources may address any concerns about the 
representativeness of patients in a trial in comparison 
with those who, for whatever reason, did not partici-
pate (eg, trial not open in the area), including checking 
that the participants are broadly representative of the 
target population. An example of this is where primary 
data were used to validate the outcomes of the real- 
world Salford Lung Studies, in the broader UK popula-
tion thereby ruling out any bias that may be introduced 
due to a regional Hawthorn effect.30 For treatments 
that are widely available outside of the research setting, 
researchers may assess external validity or representative-
ness of the patient populations if data can be requested 
for an equivalent non- randomised anonymised cohort of 
patients.11
For trials that combine multiple sources of data, trialists 
must prespecify what will be done in the instance of discrep-
ancy between sources: which source would take primacy, 
who makes that decision, how checking will be done and 
whether there is any opportunity to correct one of the data 
sources, if required, in a manner consistent with data protec-
tion regulations about holding accurate data.
It is critically important to ensure that the correct 
EHR variables are both well understood and used in the 
right way to calculate the relevant outcome measures. 
Using multiple sources with differences in terminology 
and structure requires careful, prospective analytic 
approaches to derive meaningful information about the 
safety and efficacy of treatments.
DISCUSSION
NHS datasets provide a record of population- level health 
data and afford rich opportunities for improving health 
through evidence- based medicine. There is a recognition 
that the UK can grasp these opportunities and address 
the challenges required to usher in a new generation of 
more efficient and cost- effective clinical trials. Many of 
these trials will be ‘data- enabled trials’, with routinely 
collected EHR driving their design and feasibility, their 
screening and recruitment and their management and 
analysis. Others will use EHR for more established prac-
tices such as long- term participant follow- up. The work-
shop demonstrated that EHR can readily be used to assess 
Table 5 Key points from SANAD- II trial
Trial name (registration) SANAD- II28 29 (ISRCTN30294119)
Sponsorship Academic – Liverpool.
Clinical setting Epilepsy.
Design Randomised controlled trial.
Size N=1510.
Key outcome measure Time to 12 months without seizure.
Rationale for presentation Analysis and interpretation.
Key discussion points The SANAD- II trial. SANAD- II is a pragmatic, UK, multicentre, phase IV randomised controlled 
trial funded by the National Institute for Health Research Health Technology Assessment 
programme, assessing the clinical and cost- effectiveness of a number of antiepileptic drugs as 
first- line treatments for newly diagnosed epilepsy. The primary outcome measure related to a 
period without seizures. These data were recorded on case report forms (CRFs) by the treating 
clinical team at outpatient visits.
In a study of 98 patients, the team found the seizures were poorly recorded in EHR. Using only 
EHR data estimated that 74% of patients had spent 1 year seizure free, whereas using only 
CRF data estimated that only 46% of patients had spent 1 year seizure free. This is a clinically 
important difference. Researchers need to be able to trust in the completeness of EHR data to 
use them in reliable analyses or to understand how these data might supplement CRFs. This 
example cautions against naïve use of routinely collected EHR data.
EHRs, electronic healthcare records; SANAD- II, Standard and New Antiepileptic Drugs II.
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trial feasibility and to facilitate patient recruitment from 
phase II to phase IV. However, attendees sensed that the 
short- term emphasis for conducting ‘fully data- enabled 
trials’ should be on licenced treatments in different 
populations or for new indications, where outcome 
measures are readily collectable from the EHR. Trials like 
the Salford Lung Studies and DECIDE serve as vanguards 
demonstrating the application of real- world evidence in 
fully data- enabled clinical trials.17 21 22
EHR data are collected in different formats and 
frequency depending on their purpose and provenance. 
There are multiple EHR collating- and- holding bodies 
within the UK, but no one body can provide access to all 
sources of EHR data. This situation results in a compli-
cated web of access routes to datasets, differing in scope, 
method of collection, currency of data, quality controls, 
availability of metadata and connection to additional 
linked information. It is currently estimated that fewer 
than 5% of trials in the UK successfully access routinely 
collected datasets to support trial execution,31 much 
lower than the proportion of trials planning to access 
such data at the grant application stage.32 Therefore, 
more is clearly needed to increase confidence and capa-
bilities in the use of routine health data across the UK 
clinical trials community. In the short term, route maps 
depicting these dataset details and access methods 
would be welcomed. In the long term, the trials commu-
nity would be keen to see intraoperable EHR systems 
providing simple access to up- to- date datasets to facilitate 
trials: intraoperability and reusability emerged repeatedly 
as themes throughout the workshop. There are complex 
and varying coding systems across the various healthcare 
practice settings for which clarity is required. The UK 
Secretary of State has been aware of the need for better 
data standards in healthcare and has started to put NHS 
quality data into dashboards.33 Many data items are held 
in free text so sophisticated natural language processing 
approaches will be required to extract coherent, targeted 
information, while upholding confidentiality standards. 
HDR UK’s Health Data Research Innovation Gateway has 
progressed towards making more accessible the datasets 
routinely available datasets more accessible for a range of 
research uses,34 although initially this resource is more 
likely to facilitate reuse of data from trials rather than 
supporting recruitment and conduct of new trials.
Gaining the necessary permissions to access EHR data 
causes challenges for many researchers, particularly when 
the interpretation of patient consent has changed over 
time with the strengthening information governance 
requirements. Consent from trial participants to access 
EHR data is taken in many trials only with the intention 
of accessing long- term outcome measures, so researchers 
may not submit the relevant applications until the linked 
data are needed, late in the trial. Unfortunately, expec-
tations around consent might have changed by this time 
point, complicating the process. Researchers are there-
fore strongly recommended to access EHR data from early 
in the trial and for trial consent forms to prospectively 
cover broad and enduring consent for access to routine 
EHR as a matter of course in order to facilitate research.35 
By embedding the EHR from the design stage, with 
appropriate consent, data- enabled trials avoid this issue. 
A more streamlined approach to governance with greater 
consistency and clarity in terminology and requirements 
for enduring patient consent for research may facilitate 
future data access for all trials. Where additional data are 
required and collected for a clinical trial, there may be 
potential to augment the patient’s EHR with this informa-
tion, such as results of genetic or genomic tests or patient- 
reported outcome measures.
Clinical trials are expensive and slow to plan and 
complete, and it is necessary to reduce research waste 
through all possible methods.36–39 Trial design takes at 
least 6 months yet is often insufficiently resourced, relying 
on ‘own account’ work taken at the risk of the sponsor 
(usually a higher education institute) prior to grant 
award. A substantial proportion of trials are delayed or 
do not reach their recruitment target,9 40 and a consider-
able number require at least one protocol amendment.41 
EHR offer opportunities to better plan clinical trials by 
characterising the populations and their treatment or 
diagnostic pathways as well as assessing the trial feasibility 
based around specific geographies.8 The proportion of 
patients approached and recruited to trials also varies 
according to different demographics such as ethnicity 
or age.42 43 Using EHR data to identify specific patient 
pools will enable trials in underserved populations or 
where disease burden is the greatest, thereby democra-
tising research and increasing the potential recruitment 
efficiencies.44 Increasing the representativeness of trial 
participants also enhances external validity of the find-
ings, especially as guidance such as the ‘Innovations in 
Clinical Trial Design and Delivery for the Under- served’ 
(INCLUDE) framework is now available on the issues 
to consider to be more inclusive on attributes such as 
ethnicity.45 UK- wide representative population coverage, 
through CPRD, has demonstrated the proof of principle 
of successfully recruiting a demographically representa-
tive patient population into the pragmatic DECIDE in 
type 2 diabetes trial, through centralised primary care 
patient data eligibility searches (J Valentine, personal 
communication, 2020). Virtually all of the UK popula-
tion is registered with a GP practice, and GPs are gate-
keepers to the NHS, often managing chronic conditions 
that have been diagnosed in secondary care. Barriers to 
GPs’ participation in primary healthcare research are 
well recognised.46 47 We anticipate that new, data- enabled 
methods will increase awareness of research participation 
for both patients and GPs. The role of GPs acting as poten-
tial ‘gatekeepers’ to research will be an important issue, 
recognising that ethics committees or regulators may 
require the approval of a clinician who has responsibility 
for the patient in some studies. With their rich, longitu-
dinal medical history, primary care datasets represent an 
excellent source of data to locate suitable patients for 
trials based in both primary and secondary care settings. 
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A strong desire is a single resource that brings together all 
primary care data within and across all four UK nations.
Validation of the choice of EHR codes used in patient 
cohort searches enables greater specificity of patient 
searches, leading to higher patient conversion rates into 
and less time lost by patients and trial teams at the trial 
screening stage (J Wilding, personal communication, 
2020). Clinical validation of potentially suitable patients 
initially flagged by EHR searches further refines the 
patient search, meaning that the patients approached 
to take part are more likely to pass eligibility screening, 
which improves the efficiency of patient recruitment. 
Assessment of the variables contained within the EHR at 
the trial design stage enables a better understanding of 
which variables can be obtained from routinely collected 
data, removing duplication of collection. Moving from 
only trial- specific data collection to more widespread use 
of EHR within trials should improve the cost- effectiveness 
of trial funding. Double- blinding and placebo controls 
are more difficult aspects of conduct to operationalise in 
routine EHR settings but may be offset by robust data, 
careful protocols and objective outcome measures. Each 
trial’s risk assessment should be clear on any risks asso-
ciated with the use of routine EHR data. Formal regu-
latory advice meetings may provide clarification of the 
proposed approaches, including monitoring and data 
verification. SAEs require construction by the investi-
gators of an accompanying narrative that may require 
detail beyond that collected by the research team access 
routinely collected EHR source but which should be avail-
able to the responsible investigator.
Methodological engagement, such as from MRC- NIHR 
Trials Methodology Research Partnership,48 will help to 
assess the settings for which using routinely collected 
data are, or are not, more suitable than trial- specific data 
collection. A Study Within A Trial (SWAT) approach49–51 
can efficiently assess particular elements of EHR trials, 
such as from the WOSCOPS trial.52 53 Collation of find-
ings from retrospective comparisons will elucidate issues 
for prospective clarification and highlight challenges to 
address around better data collection.26
The impact of 2020’s SARS- CoV-2 pandemic was keenly 
felt by clinical trials with many hindered by a necessary 
pause, postponement or termination of recruitment and/
or treatment. Routine hospital appointments became 
virtual and many research assessments had to follow. While 
trials teams could pivot to collect data online directly 
from participants, postponed or cancelled scans and 
tests will cause analysis and interpretation issues through 
Table 6 Key points from ASCEND trial
Trial name (registration) ASCEND: A Study of Cardiovascular Events iN Diabetes19 20 (NCT00135226)
Sponsorship Academic – Oxford.
Clinical setting Diabetes mellitus, UK only: national, mail- based methods – no study sites.
Design 2×2 factorial design randomised placebo- controlled trial (phase 4).
Size n=15 000.
Key outcome measure Cardiovascular events.
Rationale for presentation Recruitment, conduct and follow- up.
Key discussion points ASCEND used highly streamlined mail- based methods to identify, recruit and follow- up (for an 
average of 7.5 years) 15 500 UK patients, making it one of the longest duration and largest ever 
trials in diabetes.
Participants completed 6- monthly follow- up questionnaires, initially using paper, but later moving 
to an online system for those who wished.
The trialists gained access to HES data during the closing stages of the study, allowing additional 
follow- up information to be gained for those who had not returned a recent questionnaire. 
Subsequent analyses of the HES data compared with questionnaire data showed good 
concordance, suggesting that, in the UK, HES data alone could be used as a highly efficient 
means of follow- up for cardiovascular trials in the future.
HES, Hospital Episode Statistics.
Box 3 Recommendations for data- enabled trials
 ► Wider adoption of data- enabled methods for clinical trials.
 ► Build in methodology questions into the trial protocol, for example, 
conversion rates for identification to recruitment; refining the pro-
cess for identifying potential patients; understanding event rates for 
the target population.
 ► Early engagement of regulators with regards to monitoring and data 
verification.
 ► Patients and public involvement to robustly inform data- enabled 
trials.
 ► Increased interoperability of electronic health record (EHR) systems.
 ► Clear map for access to EHR: what is captured where, what do the 
data mean and how can they be used.
 ► Consistency between core outcome sets used for research and rou-
tine practice.
 ► Wider sharing and reporting of EHR code lists to support recruitment 
and outcome measures.
 ► Sharing of detailed examples of success stories.
 ► Capacity- building and capability- building for future data- enabled 
trials.
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the trial literature for many years, which will need to be 
reported systematically using the extension to Consoli-
dated Standard for Reporting Trials standards currently 
in development. National strategic prioritisation of trials 
opened doors to routinely collected data with uncommon 
rapidity. This may allow the development of new access 
routes to data for trials and more widespread adoption 
by the research community of EHR- based methodology 
within trial delivery.
The UK has led by example in patients and public 
involvement and engagement (PPIE) for trials,54 55 and 
key funding bodies support clear PPIE. Patient ambassa-
dors may be particularly helpful in informing the devel-
opment of data- enabled trials. Locating participants via 
their EHR will enable participants to be informed of the 
trial’s results which, surprisingly, still does not always 
happen, although there is limited information avail-
able on best practice to inform participants; the Show 
Respect study is addressing this.56 The StatinWISE study 
(NCT02781064), a non- randomised cohort N- of-1 study 
of stopping statins in patients who have had heart attacks, 
presented each patient a booklet of their own results 
before the study reported overall findings.57 There is a 
clear need to engage the public on clinical trials, sensi-
tising communities to research and with a specific focus 
on the capacity of EHR to provide better outcomes.
This workshop showcased key successes and high- 
profile case studies (tables 2–6) that have answered 
questions where EHR data could map well to the trial 
questions, supplemented by some trial- specific collection. 
Overinterpretation of the clinical trials regulations can be 
risk averse and suffocate innovation. Simplicity in imple-
mentation need not be interpreted as basic in ambition: 
straightforward protocols can still address a number of key 
clinical questions simultaneously.1 58 Knowledge- sharing 
and capability- building exercises now should facilitate 
future data- enabled trials. Triallists are getting better at 
writing up their findings and, increasingly, their designs, 
but further effort is required in writing up their prac-
tical implementation experiences. Best practice and case 
studies, reflecting on successes and challenges, should 
be shared, including in the threaded publications from 
NIHR Health Technology Assessment monographs59 or a 
new, dedicated national forum.
Five years previously, NIHR launched a call for trials 
using routinely collected data that elicited a modest 
response form research community. Stimulating research 
using routinely collected clinical data has remained a 
sustained interest of NIHR, and launching out from this 
workshop, NIHR announced a new call for data- enabled 
trials.4 NIHR committees reviewed 18 applications and 
the funded trials were confirmed in 2020 (table 1).
Routinely collected EHR offer great potential for 
faster, more efficient and less expensive trials reaching a 
broader catchment of the UK population. Wider adop-
tion of EHR- based approaches and experiences from 
these studies, such as those funded from the NIHR data- 
enabled trial call, will provide the evidence to assess 
where EHR enablement brings benefits to trial execution 
and follow- up. Key recommendations from the workshop 
are presented in box 3, many of which are now being 
addressed. Using EHR data for trials can be done and 
could be done at a greater scale than is the current prac-
tice. The desire to access and efficiently use these data 
is widely discussed, and this workshop demonstrated that 
this aspiration is possible. The opportunities to learn 
and harness the power of information and technology 
to improve healthcare outcomes for everyone has never 
been better.
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